11355927

Source:http://linkedlifedata.com/resource/pubmed/id/11355927

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0005532, umls-concept:C0023418, umls-concept:C0087111, umls-concept:C0175668
pubmed:issue	1
pubmed:dateCreated	2001-5-17
pubmed:abstractText	Secondary leukaemias are common, accounting for more than 40% of all patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS). A clinical history of exposure to haematotoxins or radiation is helpful; however, many older patients are diagnosed with leukaemia with no antecedent history of exposure. These patients' disease show a remarkably similar phenotype to classic therapy-related leukaemia. The specific cytogenetic abnormalities common to MDS, alkylating-agent-related AML and poor-prognosis AML (3q-, -5, 5q-, -7, 7q-, +8, +9, 11q-, 12p-, -18, -19,20q-, +21, t(1;7), t(2;11)), probably reflect a common pathogenesis distinct from that of other de novo AMLs, although the pathogenetic pathway has yet to be elucidated. Possibly, tumour suppressor genes are implicated and genomic instability may be a cause of multiple unbalanced chromosomal translocations or deletions. Typically, these patients are either elderly or have a history of exposure to alkylating agents or environmental exposure 5-7 years prior to diagnosis. Another distinct entity affects the mixed lineage leukaemia (MLL) gene located on 11q23. These account for about 3% of patients with therapy-related leukaemia and have a short latency period from exposure, usually to an inhibitor of topoisomerase II. Other therapy-related patients with t(8:21), inv16 or t(15;17) translocations should be treated as any other de novo AML with similar cytogenetics. In summary, the major prognostic factor is related to the pathogenetic mechanisms of the leukaemia. Cytogenetics and molecular features are a better predictor of outcome than patient history. Patients should receive standard induction therapy. However, the long-term outcome is relatively poor; the best results being obtained among patients undergoing allogeneic transplantation.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101120659
pubmed:citationSubset	IM
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	1521-6926
pubmed:author	pubmed-author:DannE JEJ, pubmed-author:RoweJ MJM
pubmed:copyrightInfo	Copyright 2001 Harcourt Publishers Ltd.
pubmed:issnType	Print
pubmed:volume	14
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	119-37
pubmed:dateRevised	2005-11-16
pubmed:meshHeading	pubmed-meshheading:11355927-Cytogenetics, pubmed-meshheading:11355927-Humans, pubmed-meshheading:11355927-Leukemia, pubmed-meshheading:11355927-Myelodysplastic Syndromes, pubmed-meshheading:11355927-Neoplasms, Second Primary, pubmed-meshheading:11355927-Risk Factors
pubmed:year	2001
pubmed:articleTitle	Biology and therapy of secondary leukaemias.
pubmed:affiliation	Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Haifa, 31096, Israel.
pubmed:publicationType	Journal Article, Review